| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/vir-biotechnology-vir-ceo-sells-73000-shares-664000","as_of":"2026-04-12T14:47:21.649613+00:00","canonical_url":"https://www.fool.com/coverage/filings/2026/04/12/vir-biotechnology-vir-ceo-sells-73-000-shares-for-usd664-000/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/vir-biotechnology-vir-ceo-sells-73000-shares-664000","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_72e30bbbf735ba11","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/coverage/filings/2026/04/12/vir-biotechnology-vir-ceo-sells-73-000-shares-for-usd664-000/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-12T17:46:45.885769+00:00","extraction_method":"trafilatura","fetched_description":"Key Points72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026.","fetched_title":"Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 | Nasdaq","final_url":"https://www.nasdaq.com/articles/vir-biotechnology-vir-ceo-sells-73000-shares-664000","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/vir-biotechnology-vir-ceo-sells-73000-shares-664000","source_event_id":"evt_ad075862fb36","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"ce116455a66c8c65","kind":"unusual_volume","published_at":"2026-04-12T13:33:42+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 6, 2026","February 2026","late 2022","early 2023","April 12, 2026","December 17, 2004","April 15, 2005"],"entities":[{"asset_class":"equity","name":"Vir Biotechnology, Inc.","relevance":"high","symbol":"VIR","type":"company"},{"asset_class":"equity_insider","name":"Marianne De Backer","relevance":"high","symbol":"","type":"person"},{"asset_class":"trust","name":"Ureel-De Backer Family Trust","relevance":"medium","symbol":"","type":"entity"}],"event_type":"other","information_gaps":["Unconfirmed volume delta: the provided text does not include any volume ratio vs average or unusual trading volume metrics.","No explicit confirmation from external news sources is provided beyond the SEC Form 4-based insider sale framing.","The article provides a catalyst hypothesis (periodic income supplementation) but does not link the sale to a specific immediate company event on the same date.","catalyst_hypothesis_most_likely_unstated_in_schema? (captured below) "],"key_facts":["President and CEO Marianne De Backer reported the sale of 72,559 shares in an open-market transaction on April 6, 2026, according to an SEC Form 4 filing.","The transaction value was about $664,000.","The reported sale price was $9.16 per share (based on SEC Form 4).","The sale represented 6.76% of De Backer\u2019s total holdings at the time of the transaction.","The article states there was no activity reported in indirect accounts such as the Ureel-De Backer Family Trust.","The article states no derivative securities or option exercises were reported; the sale was exclusively in directly held common stock.","The article claims this sale continues a pattern of periodic disposals, with the average size of her four most recent open-market sales at about 60,000 shares.","After the sale, De Backer retained 948,145 shares directly and 53,118 shares indirectly through the Ureel-De Backer Family Trust.","The article notes the stock had appreciated 79.92% over the prior year as of April 6, 2026 (context for the sale price)."],"numeric_claims":[{"label":"shares_sold","value":"72,559"},{"label":"transaction_value_usd","value":"~664,000"},{"label":"reported_sale_price_usd_per_share","value":"9.16"},{"label":"percent_of_total_holdings_sold","value":"6.76%"},{"label":"direct_shares_after","value":"948,145"},{"label":"indirect_shares_after","value":"53,118"},{"label":"average_recent_open_market_sales_shares","value":"~60,000"},{"label":"stock_appreciation_prior_year_percent","value":"79.92%"}],"primary_claim":"On April 6, 2026, Vir Biotechnology CEO Marianne De Backer sold 72,559 shares for approximately $664,000 in an open-market transaction reported on an SEC Form 4 filing.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Vir Biotechnology CEO Marianne De Backer sold 72,559 shares in an open-market transaction on April 6, 2026 for about $664,000, per an SEC Form 4 filing. The article frames the sale as part of a recurring periodic disposal pattern rather than an exit.","topics":["insider trading","SEC Form 4","CEO share sale","ownership reduction","periodic disposals","Vir Biotechnology business context"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key Points72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026.","tickers":["VIR"],"title":"Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000","url":"https://www.fool.com/coverage/filings/2026/04/12/vir-biotechnology-vir-ceo-sells-73-000-shares-for-usd664-000/"}... |